Recent results from the ASPIRE trial aimed to determine the effects of a vaginal ring containing dapivirine—an antiviral, non-nucleoside reverse transcriptase inhibitor—on risk of drug resistant HIV, and...
According to recently filed complaints with the Department of Health and Human Services' Office for Civil Rights, some marketplace plans are making drugs that people with HIV need unavailable or...
A cohort of HIV-positive children in southern Africa who retain near-normal immune systems could shed light on HIV pathogenesis, which may help develop future treatments for the disease.
A recent study revealed factors responsible for the creation of broadly neutralizing antibodies that target various sub-types of HIV, a discovery that could direct efforts to develop an HIV vaccine.
A recent study examined the incidence of hepatocellular carcinoma and other causes of liver-related deaths in individuals coinfected with human immunodeficiency virus and hepatitis C virus.
Research presented at the Conference on Retroviruses and Opportunistic Infections details the success of sofosbuvir/ledipasvir therapy in individuals with both HIV and hepatitis C infection.
A clinical trial tested the effectiveness of the dapivirine ring, which releases an anti-retroviral drug in the vagina to protect women against HIV infection.
